The guanine-nucleotide exchange factor Vav is a crucial regulator of B cell receptor activation and B cell responses to nonrepetitive antigens

Journal of Immunology

Volumn 163, Issue 1, 1999, Pages 137-142

  Bachmann, Martin F ^a   Nitschke, Lars ^b   Krawczyk, Connie ^c   Tedford, Kerry ^b   Ohashi, Pamela S ^c   Fischer, Klaus D ^b   Penninger, Josef M ^c  

^a BASEL INSTITUTE FOR IMMUNOLOGY   (Switzerland)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD40 ANTIGEN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; LYMPHOCYTE ANTIGEN RECEPTOR; TRINITROPHENYL; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CROSS LINKING; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS; ANTIGENS, VIRAL; B-LYMPHOCYTES; CELL CYCLE PROTEINS; GUANINE NUCLEOTIDES; HAPTENS; IMMUNOGLOBULIN M; INJECTIONS, INTRAVENOUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITROPHENOLS; OVALBUMIN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-VAV; RECEPTORS, ANTIGEN, B-CELL; VESICULAR STOMATITIS-INDIANA VIRUS;

EID: 0033168892     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Fischer, K.-D., K. Tedford, and J. M. Penninger. 1993. Vav links antigen-receptor signaling to the actin cytoskeleton. Semin. Immunol. 260:358.
2. Collins, T. L., M. Deckert, and A. Altman. 1997. Views on Vav. Immunol. Today 18:221.
3. Katzav, S., Z.-D. Martin, and M. Barbadd. 1989. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J. 8:2283.
4. Henning, S. W., and D. A. Cantrell. 1998. GTPases in antigen receptor signalling. Curr. Opin. Immunol. 10:322.
5. Margolis, B., P. Hu, S. Katzav, W. Li, J. M. Oliver, A. Ullrich, A. Weiss, and J. Scnlessinger. 1992. Tyrosine phosphorylation of vor proto-oncogene product containing SH2 domain and transcription factor motifs. Nature 356:71.
6. Bustelo, X. R., J. A. Ledbetter, and M. Barbacid. 1992. Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature 356: 68.
7. Knaus, U. G., S. Morris, H. J. Dong, J. Chernoff, and G. M. Bokoch. 1995. Regulation of human-leukocyte P21-activated kinases through G-protein-coupled receptors. Science 269:221.
8. Tapon, N., and A. Hall. 1997. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr. Opin. Cell Biol. 9:86.
9. Crespo, P., K. E. Schuebel, A. A. Ostrom, J. S. Gutkind, and X. R. Bustelo. 1997. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature 385:169.
10. Han, J. W., B. Das, W. Wei, L. Vanaelst, R. D. Mosteller, R. Khosravifar, J. K. Westwick, C. J. Der, and D. Broek. 1997. Lck regulates Vav activation of members of the Rho-family of GTPase. Mol. Cell. Biol. 17:1346.
11. Crespo, P., X. R. Bustelo, D. S. Aaronson, O. A. Coso, M. Lopezbarahona, M. Barbacid, and J. S. Gutkind. 1996. Rac-1 dependent stimulation of the JNK/ SAPK signaling pathway by Vav. Oncogene 13:455.
12. Fischer, K. D., Y. Y. Kong, H. Nishina, K. Tedford, L. E. M. Marengere, I. Kozieradzki, T. Sasaki, M. Starr, G. Chan, S. Gardener, M. P. Nghiem, D. Bouchard, M. Barbacid, A. Bernstein, and J. M. Penninger. 1998. Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor. Curr. Biol. 8:554.
13. Holsinger, L. J., I. A. Graef, W. Swat, T. Chi, D. M. Bautista, L. Davidson, R. S. Lewis, F. W. Alt, and G. R. Crabtree. 1998. Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction. Curr. Biol. 8:563.
14. + thymocytes. Nature 374:474.
15. Turner, M., P. J. Mee, A. E. Walters, M. E. Quinn, A. L. Mellor, R. Zamoyska, and V. L. J. Tybulewicz. 1997. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 7:451.
16. Zhang, R., F. W. Alt, L. Davidson, S. H. Orkin, and W. Swat. 1995. Defective signalling through the T-and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene. Nature 374:470.
17. Tarakhovsky, A., M. Turner, S. Schaal, P. J. Mee, L. P. Duddy, K. Rajewsky, and V. L. Tybulewicz. 1995. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 374:467.
18. Wu, J., D. G. Motto, G. A. Koretzky, and A. Weiss. 1996. Vav and Slp-76 interact and functionally cooperate in IL-2 gene activation. Immunity 4:593.
19. Raab, M., A. J. da Silva, P. R. Findell, and C. E. Rudd. 1997. Regulation of Vav-SLP-76 binding by ZAP-70 and its relevance to TCR UCD3 induction of interleukin-2. Immunity 6:155.
20. vav associates with tyrosine-phosphorylated SLP-76 in antigen-stimulated T cells. J. Exp. Med. 184:1161.
21. Guinamard, R., M. Fougereau, and P. Seckinger. 1997. The SH3 domain of Bruton's tyrosine kinase interacts with Vav, Sam68 and EWS. Scand. J. Immunol. 45:587.
22. Weng, W. K., L. Jarvis, and T. W. LeBien. 1994. Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human B cell precursors. J. Biol. Chem. 269:32514.
23. O'Rourke, L. M., R. Tooze, M. Turner, D. M. Sandoval, R. H. Carter, V. L. J. Tybulewicz, and D. T. Fearon. 1998. CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav. Immunity 8:635.
24. Sato, S., P. J. Jansen, and T. F. Tedder. 1997. CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling. Proc. Natl. Acad. Sci. USA 94:13158.
25. Nishina, H., M. Bachmann, A. J. Oliveiradossantos, I. Kozieradzki, K. D. Fischer, B. Odermatt, A. Wakeham, A. Shahinian, H. Takimoto, A. Bernstein, T. W. Mak, J. R. Woodgett, P. S. Ohashi, and J. M. Penninger. 1997. Impaired CD28-mediated interleukin-2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1) mitogen-activated protein-kinase kinase-4 (MKK4)-deficient T-lymphocytes. J. Exp. Med. 186:941.
26. Cheng, G., A. M. Cleary, Z. S. Ye, D. I. Hong, S. Lederman, and D. Baltimore. 1995. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 267:1494.
27. Roost, H., S. Charan, R. Gobet, E. Rueedi, H. Hengartner, A. Althage, and R. M. Zinkernagel. 1988. An acquired immune suppression in mice caused by infection with lymphocytic choriomeningitis virus. Eur. J. Immunol. 18:511.
28. Mond, J. J., A. Lees, and C. M. Snapper. 1995. T cell-independent antigens type 2. Annu. Rev. Immunol. 13:655.
29. Bachmann, M. F., U. Kalinke, A. Althage, G. Freer, C. Burkhart, H. Roost, M. Aguet, H. Hengartner, and R. M. Zinkernagel. 1997. The role of antibody concentration and avidity in antiviral protection. Science 276:2024.
30. Bachmann, M. F., and R. M. Zinkernagel. 1997. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15:235.
31. Bachmann, M. F., and R. M. Zinkernagel. 1996. The influence of virus structure on antibody responses and virus serotype formation. Immunol. Today 17:553.
32. Leist, T. P., S. P. Cobbold, H. Waldmann, M. Aguet, and R. M. Zinkernagel. 1987. Functional analysis of T lymphocyte subsets in antiviral host defense. J. Immunol. 138:2278.
33. Bachmann, M. F., and T. M. Kuendig. 1994. In vivo versus in vitro assays for assessment of T-and B-cell function. Curr. Opin. Immunol. 6:320.
34. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kuendig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609.
35. Tarakhovsky, A. 1997. Bar Mitzvah for B-1 cells: how will they grow up? J. Exp. Med. 185:981.
36. Rickert, R. C., K. Rajewsky, and J. Roes. 1995. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376: 352.
37. Engel, P., L. J. Zhou, D. C. Ord, S. Sato, B. Koller, and T. F. Tedder. 1995. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3:39.
38. Satterthwaite, A. B., H, Cheroutre, W. N. Khan, P. Sideras, and O. N. Witte. 1997. Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc. Natl. Acad. Sci. USA 9:13152.
39. Khan, W. N., F. W. Alt, R. M. Gerstein, B. A. Malynn, I. Larsson, G. Rathbun, L. Davidson, S. Mueller, A. B. Kantor, L. A. Herzenberg, et al. 1995. Defective B cell development and function in Btk-deficient mice. Immunity 3:283.
40. Snapper, S. B., F. S. Rosen, E. Mizoguchi, P. Cohen, W. Khan, C. H. Liu, T. L. Hagemann, S. P. Kwan, R. Ferrini, L. Davidson, A. K. Bhan, and F. W. Alt. 1998. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 9:81.
41. Defranco, A. L. 1995. Transmembrane signaling by antigen receptors of B-lymphocytes and T-lymphocytes. Curr. Opin. Cell Biol. 7:163.
42. Deckert, M., S. Tartaredeckert, C. Couture, T. Mustelin, and A. Altman. 1996. Functional and physical interactions of Syk family kinases with the Vav protooncogene product. Immunity 5:591.
43. Graziadei, L., K. Riabowol, and S.-D. Bar. 1990. Co-capping of ras proteins with surface immunoglobulins in B lymphocytes. Nature 347:396.
44. + T cells in persistent infection with lymphocytic choriomeningitis virus. J. Exp. Med. 187:1903.